viewBetterLife Pharma Inc

BetterLife Pharma reveals clinical trial updates on its treatment for mild-to-moderate coronavirus cases

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate coronavirus cases at research sites across Australia.

Doroudian says the clinical trial, expected to launch later this year, will test AP-003, BetterLife’s inhaled recombinant human alpha 2b interferon drug, against a placebo. The trial, which the company claims is the first of its kind in Australia, is expected to recruit 150 patients.

Quick facts: BetterLife Pharma Inc

Price: 1.23 USD

Market: OTCQB
Market Cap: $61.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...


BetterLife surges on UK biotech trial results of interferon inhalation...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian tells Proactive its encouraged by positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus reduces the need for intensive care. Doroudian says data from...

on 07/23/2020

2 min read